Longer follow-up of a phase 3 trial in 457 adults with extensive-stage SCLC: first-line tislelizumab plus chemotherapy kept its overall survival benefit vs placebo plus chemotherapy (median 15.5 vs 13.5 months; HR 0.78), with no new safety signals.
Secondary analysisn = 457
Fan et al. First-Line Tislelizumab Plus Chemotherapy Versus Placebo Plus Chemotherapy in Extensive-Stage SCLC: A Long-Term Survival and Programmed Death-Ligand 1 Subgroup Analysis From the Randomized, Phase 3 RATIONALE-312 Trial